New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
09:11 EDTMRK, X, RGDO, THI, ADXS, TRP, RHHBY, BKW, QIHU, INSY, ITMNOn The Fly: Pre-market Movers
HIGHER: Burger King (BKW), up 13% after confirming talks regarding a potential strategic transaction with Tim Hortons (THI). Shares of the Canadian donut shop operator trading in New York are also up 17%... InterMune (ITMN), up 36% after Roche (RHHBY) agreed to acquire the company for $74.00 per share... Advaxis (ADXS), up 4% after entering clinical trial collaboration agreement with Merck (MRK)... Insys Therapeutics (INSY), up 5.5% after receiving FDA orphan drug designation for CBD... TransCanada (TRP), up 2.2% after Barron's says the company could climb 35%... U.S. Steel (X), up 3.7% after upgraded at Credit Suisse. LOWER: Regado (RGDO), down 52% after the company terminated enrollment in its REGULATE-PCI Phase 3 trial... Qihoo 360 (QIHU), down 5% after reporting Q2 earnings, Q3 outlook.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 17, 2015
10:11 EDTINSYOptions with decreasing implied volatility
Subscribe for More Information
09:18 EDTADXSAdvaxis to receive $1.6M through NJ NOL Program
Advaxis announced the company has received preliminary approval for a $1.8M tax credit from the New Jersey Technology Business Tax Certificate Transfer, or NOL, Program for the year 2015. The company anticipates it will be able to transfer this credit and receive approximately $1.6M in cash in December.
08:04 EDTMRKMerck to present new KEYTRUDA findings at upcoming congresses
Merck announced that data investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year. In total, data from more than 30 abstracts will be presented at the Society for Melanoma Research 2015 Congress in San Francisco, Nov. 18 - 21; the 57th American Society of Hematology Annual Meeting in Orlando, Florida, Dec. 5 - 8; the San Antonio Breast Cancer Symposium, Dec. 8 - 12; and the European Society for Medical Oncology Asia 2015 Congress in Singapore, Dec. 18 - 21. By the end of 2015, data on the anti-tumor activity of KEYTRUDA will have been presented across more than 20 tumor types. "The field of immuno-oncology holds great potential across a broad spectrum of cancers," said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research Laboratories. "Data for KEYTRUDA being presented at these scientific meetings include a first-time comparison to chemotherapy in advanced non-small cell lung cancer, novel combination data in advanced melanoma as well as first-time data in two additional tumor types, namely multiple myeloma and hormone receptor positive breast cancer, further demonstrating our deep commitment to advancing cancer treatment."
07:34 EDTRHHBYOphthotech to hold a conference call
Subscribe for More Information
06:24 EDTTRPEnbridge reduces workforce in Canada, U.S. by 5%, Reuters says
Subscribe for More Information
06:08 EDTRHHBYRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information
November 16, 2015
10:25 EDTINSYOptions with decreasing implied volatility
Subscribe for More Information
09:06 EDTINSYDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
08:41 EDTTRPTransCanada subsidiary signs contracts
Subscribe for More Information
08:35 EDTMRKMerck to present Phase 2 hep C therapy data at The Liver Meeting
Subscribe for More Information
07:24 EDTMRKSalomon to hold a conference
Subscribe for More Information
05:38 EDTXU.S. Steel implied volatility of 102 at upper end of index mean range
November 15, 2015
15:19 EDTMRKMerck reports integrated analysis of six trials of elbasvir/grazoprevir
Subscribe for More Information
15:15 EDTMRKMerck reports Phase 3 data on elbasvir/grazoprevir in patients injecting drugs
Subscribe for More Information
November 13, 2015
10:18 EDTRHHBYRoche receives FDA approval for cobas EGFR mutation test
Subscribe for More Information
09:34 EDTRHHBYFDA approves Roche's cobas EGFR Mutation Test
Subscribe for More Information
08:02 EDTMRKMerck: DMC recommends anacetrapib study continue with no changes
Subscribe for More Information
November 12, 2015
17:02 EDTMRKMerck Animal Health to Acquire Harrisvaccines
Merck Animal Health and Harrisvaccines announced the companies have entered into an agreement under which Merck Animal Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and sells vaccines for food production and companion animals. The terms of the agreement were not disclosed. The companies expect the transaction to close in the fourth quarter of 2015.
11:50 EDTRHHBYRoche to restructure manufacturing network for small molecules
Subscribe for More Information
11:50 EDTMRKMerck issues statement regarding CUBICIN patent litigation
Merck issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit: "The decision validated the patent for CUBICIN that expires on June 15, 2016, but invalidated four patents with expiration dates in 2019 and 2020. The company is reviewing the decision and is considering its next steps, which may include seeking further review at the Federal Circuit or Supreme Court."
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use